O-5 Novel HLA II associations in myasthenia gravis

O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients C. Angelini, C. Semplicini, E. Pegoraro, M. Filosto, G. Marrosu R. Piras, T. Mongini, L. Vercelli, P. Tonin, S. Servidei, R. Di Giacopo, G. Crescimanno, S. Ravaglia, A. Toscano, O. Musumeci, G. Siciliano, G. Ricci, Di Iorio, F. Cipullo, M. Moggio, G. Comi, V. Lucchini, L. Morandi 1 University of Padova, Department of Neurosciences, Padova, Italy; 2 Hospital of Brescia, Italy; 3 University of Cagliari, Italy; 4 University of Torino, Centre for Neuromuscular Diseases, Department of Neurosciences, Torino, Italy; 5 University of Verona; 6 Catholic University of Rome, Italy; 7 University of Palermo, Italy; 8 University of Pavia, Italy; 9 Department of Neurosciences, Psichiatry and Anesthesiology, University of Messina, Italy; 10 University of Pisa, Italy; 11 Second University of Napoli; 12 Deparment of Neurological Sciences, University of Milan, Italy; 13 Besta Institute, Milan, Italy